Terence Herman
Medical Oncology · Harlingen, TXNPI 1124097498
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,498 and has fallen 98.9% since, to $17 in 2024. That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.
Across 100 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$291
- Seagen Inc.$173
- Bristol Myers Squibb$141
- Daiichi Sankyo Inc.$137
- Sobi, Inc$125
- Lilly USA, LLC$119
- plus $872 from 26 others
What the payments were for
- Food & beverage$1,81398%
- Education$442%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 15 | $291 |
| Seagen Inc. | 11 | $173 |
| Bristol Myers Squibb | 6 | $141 |
| Daiichi Sankyo Inc. | 7 | $137 |
| Sobi, Inc | 6 | $125 |
| Lilly USA, LLC | 7 | $119 |
| Sanofi | 4 | $91 |
| Eisai Inc. | 5 | $87 |
| Bayer | 3 | $58 |
| E.r. Squibb & Sons, L.L.C. | 3 | $57 |
| Gilead | 3 | $55 |
| Astellas Pharma US Inc | 3 | $51 |
| Genentech USA, Inc. | 2 | $50 |
| Jazz Pharmaceuticals Inc. | 2 | $44 |
| Johnson & Johnson | 2 | $38 |
| Novartis | 2 | $35 |
| EMD Serono, Inc. | 2 | $31 |
| Tolmar, Inc. | 2 | $31 |
| Brainlab, Inc. | 1 | $25 |
| GSK | 1 | $22 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| Pharmaessentia USA Corporation | 1 | $18 |
| AstraZeneca | 1 | $18 |
| Novocure Inc. | 1 | $18 |
| Array Biopharma Inc | 1 | $17 |
| GT Medical Technologies, Inc | 1 | $17 |
| Pharming Healthcare, Inc. | 1 | $17 |
| Immunogen, Inc. | 1 | $17 |
| Mevion_medical_systems_inc | 2 | $16 |
| Amgen | 1 | $14 |
| AVEO Pharmaceuticals, Inc. | 1 | $13 |
| Karyopharm Therapeutics Inc. | 1 | $13 |
How this compares
$1,857 in reported general payments places this provider in the 30th percentile of 495 medical oncology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exemestane | 12 | $4,411 |
| Amlodipine Besylate | 13 | $116 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Harlingen
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Vijay GunugantiSan Antonio$1.5M
- Sue EckhardtAustin$1.5M
- Joyce O'ShaughnessyDallas$1.3M
- Ronan KellyDallas$1.1M
- Maen AbdelrahimHouston$999K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.